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Abstract Recent evidence indicates that the type II transform-
ing growth factor-L (TGF-L) receptor (TLRII) is a serine-
threonine-tyrosine kinase. However, the significance of its
tyrosine kinase is unclear. We investigated in vascular smooth
muscle cells the effects of tyrosine kinase inhibition on the
expression of TGF-L receptor types I (ALK-5) and II (TLRII)
mRNA, induced by TGF-L1. TGF-L1 elevated ALK-5 mRNA
levels 5-fold; essentially similar TGF-L1-dependent elevations
were observed with growth factors, PDGF-BB and FGF-2. The
tyrosine kinase inhibitor genistein abolished these TGF-L1 and
growth factor responses. TGF-L1 also elevated TLRII mRNA
levels which were not inhibited by genistein. We conclude that
tyrosine kinases participate in defining how cells respond to
TGF-L.
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1. Introduction
The importance of protein phosphorylation in signalling
events associated with smooth muscle cell proliferation and
blood vessel remodelling is well documented. Most mitogenic
growth factors interact with transmembrane tyrosine kinases,
initiating autophosphorylation and triggering a cascade of
phosphorylation events critical for cell proliferation [1,2].
These latter events can involve tyrosine kinases, serine/threo-
nine kinases as well as dual speci¢c kinases such as mitogen-
activated protein (MAP) kinase which activates its substrate
by phosphorylation on both tyrosine and threonine residues
[3,4]. There is also evidence that members of the transforming
growth factor-beta (TGF-L) family which regulate cell
growth, di¡erentiation and gene responses [5^7], also interact
with receptors which can initiate phosphorylation on tyrosine,
serine and threonine residues [8,9]. Signal transduction by
TGF-L is dependent on the physical interaction of its type I
and type II receptors, namely ALK-5 or ALK-2 and TLRII,
forming a heteromeric complex at the cell surface and result-
ing in phosphorylation of the type I receptor on serine and
threonine [10]. Types I and II receptors also exist in the sur-
face membrane as homomeric receptor complexes [11] and in
the case of the type II receptor, its cytoplasmic domain is
constitutively autophosphorylated [12]. Recently its phospho-
rylation has been shown to involve not only serine and threo-
nine but also tyrosine, and replacement of tyrosine residues
with phenylalanine strongly inhibits its kinase activity [9]. The
in vivo biological signi¢cance of tyrosine phosphorylation in
the TGF-L initiated signalling cascade is not known. It is
possible that tyrosine phosphorylation in£uences the pattern
of TGF-L-inducible cell responses. We tested this hypothesis
in cultured smooth muscle cells by examining the ability of
exogenous and endogenously produced TGF-L1 to increase
the expression of the TGF-L receptors, types I (ALK-5 and
ALK-2) and type II (TLRII), in the absence and presence of
tyrosine kinase inhibition. We demonstrate that tyrosine kin-
ase activity is essential for the induction by TGF-L1 of ex-
pression of its types I but not its type II receptor, suggesting
di¡erentiation of signalling through tyrosine phosphorylation
mechanisms.
2. Materials and methods
2.1. Cell culture
Vascular smooth muscle cells (VSMC) were obtained from the me-
dia of rat left common carotid arteries as previously described [6,13].
VSMC were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 10% fetal bovine serum and were used between
the 2nd and 6th passage. At con£uency the VSMC were serum-de-
prived for 24 h and then incubated with either PDGF-BB (200 ng/ml,
Sigma, St Louis, MO, USA), FGF-2 (50 ng/ml, Bachem, Torrence,
CA, USA), or TGF-L1 (2 ng/ml, Celltrix, Palo Alto, CA, USA) in
DMEM or with DMEM alone. The cells were harvested 24 h later
and the RNA immediately extracted (see below). Some experiments
(see Section 3) were performed in the presence of a TGF-L1-neutralis-
ing antibody (Becton Dickinson, MA, USA, 2.5 Wg/ml [0.72 Wg neu-
tralises 1 ng TGF-L1]), or the tyrosine kinase inhibitor genistein (200
WM, RBI, Natick, NJ, USA) at concentrations previously been shown
by us and others to speci¢cally inhibit the actions of TGF-L1 and
tyrosine kinases, respectively [6,14].
2.2. RNA extraction and standardised reverse transcriptase-polymerase
chain reaction (sRT-PCR)
Total RNA was extracted from cells using the method of Chom-
czynski and Sacchi [15], then treated with DNase (Stratagene). The
RNA was dissolved in sterile water to a concentration of 266 ng/Wl.
Two hundred nanograms were then used for each reverse transcrip-
tase-polymerase chain reaction (RT-PCR). A standardised (s)RT-PCR
was performed in a manner which ensured that the respective PCR
products re£ected the levels of mRNA encoding the di¡erent TGF-L
receptors in VSMC, as previously described (for details see [6,16]).
This was performed using the following oligonucleotide primers and
cycles: ALK-5 sense, base pairs (bp) 70^102 and antisense, bp 484^
513, 34 cycles; ALK-2 sense, bp 128^152 and antisense, bp 435^459,
for 34 cycles; TLRII sense, bp 1214^1237 and antisense, bp 1525^
1552. The amount of PCR product for each target mRNA was ex-
pressed relative to the amount of PCR product for L7, a ribosomal
protein which is encoded by a non-inducible cell cycle-independent
gene [17] using the following primers and cycle number: sense, bp
143^162 and antisense, bp 405^428 for 23 cycles. PCR products
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were quantitated using laser densitometry estimation of intensities
from photograph negatives of 2% agarose electrophoresis gels [6].
3. Results
3.1. E¡ects of growth factors on expression of TGF-L
receptor mRNAs in VSMC
Initially we examined how exposure of VSMC to TGF-L1
a¡ected mRNA levels encoding the type I TGF-L receptors,
ALK-5 and ALK-2, and the type II receptor (TLRII). Twenty
four hours exposure of the cells to TGF-L1 (2 ng/ml) elevated
ALK-5 mRNA levels 8.3-fold; ALK-2 was also elevated at
this time by 2.5-fold (Fig. 1). TGF-L1 was also a potent stim-
ulator of TLRII gene expression in these cells elevating
mRNA levels during the 24-h period by 5.2-fold. Since
TGF-L1 is known to be induced in VSMC by PDGF-BB
and FGF-2 we next investigated the extent to which these
growth factors increased mRNA encoding the type I and
type II TGF-L receptors. Twenty four hours exposure of these
cells to PDGF-BB (200 ng/ml) resulted in elevated ALK-5
mRNA levels by 5.8-fold, an increase in ALK-2 mRNA by
2.5-fold and TLRII mRNA by 3.9-fold (Fig. 1); FGF-2 (50
ng/ml) also elevated ALK-5 mRNA (by 6.6-fold), ALK-2
mRNA by 2.0-fold and TLRII by 4.8-fold (Fig. 1).
3.2. Inhibition of tyrosine kinase activity alters the pro¢le
of TGF-L receptor mRNAs induced by TGF-L1
Since the type II TGF-L receptor is known to undergo
tyrosine phosphorylation in vitro, we next investigated the
extent to which tyrosine kinase activities might regulate in-
duction of types I and type II receptor mRNA by TGF-L1.
Simultaneous exposure of the VSMC to TGF-L1 (2 ng/ml)
and 200 WM genistein, a concentration which maximally and
speci¢cally inhibits tyrosine kinases in vascular smooth muscle
[6] without a¡ecting serine/threonine kinases, Ca2-dependent
calmodulin and related kinases [14], completely prevented the
cytokine-induced elevations in ALK-2 and ALK-5 mRNA
levels (Figs. 2 and 3). In contrast genistein did not a¡ect the
ability of TGF-L1 to elevate mRNA encoding TLRII (Figs. 2
and 3), providing evidence that distinct tyrosine kinase-de-
pendent and -independent pathways are involved in the regu-
lation of mRNAs of the two classes of receptor in response to
TGF-L1. Genistein (200 WM) also inhibited PDGF-BB and
FGF-2 induced elevations in ALK-2, ALK-5 and TLRII
mRNA in the cultures (Fig. 3), consistent with its high e⁄cacy
for inhibition of tyrosine kinase activities in vascular smooth
muscle [6]. Thus, tyrosine phosphorylation appears necessary
for the control of speci¢c responses to TGF-L1 in VSMC.
3.3. Dependency of induction of types I and II TGF-L receptors
in VSMC on autocrine actions of TGF-L1
Since exogenously added TGF-L1 markedly elevated
mRNA levels encoding the type I receptors ALK-5 and
ALK-2 and also TLRII, it was of interest to determine
whether increased secretion of this cytokine by VSMC could
also cause similar elevations in mRNA levels. Accordingly, we
next examined, using TGF-L1-speci¢c neutralising antibodies,
the extent to which endogenously secreted, biologically active
TGF-L1 is responsible for the ability of RTKGFs to increase
mRNA levels encoding the di¡erent TGF-L receptor types.
The TGF-L1 neutralising antibody (2.5 Wg/ml) completely pre-
vented the ability of TGF-L1 (2 ng/ml) to elevate the mRNAs
encoding ALK-5, ALK-2 and TLRII (Fig. 4). However this
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Fig. 1. Agarose gels depicting RT-PCR analysis of type I (ALK-5
and ALK-2) and type II (TLRII) TGF-L receptor and L7 mRNA
levels in cultured vascular smooth muscle cells after 24 h exposure
to PDGF-BB (P), FGF-2 (F) or TGF-L1 (T) or culture medium
only (C). M represents molecular weight markers from xX174
DNA digested with HaeIII (Promega, WI, USA). Results are typical
of 6 experiments.
Fig. 2. Dependency of elevations in TGF-L receptor mRNAs on tyrosine phosphorylation in cultured vascular smooth muscle cells during 24
hours incubation with PDGF (P), FGF (F) and TGF-L1 (T) in the presence of the tyrosine kinase inhibitor genistein. C represents control
(growth factor stimulated in the absence of genistein). Results are expressed relative to mRNA levels of L7 and are the mean of 3 experiments.
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concentration of antibody, which we have previously shown
prevents TGF-L1-dependent increases in integrin Kv induced
by PDGF-BB in these cells [6], had only a minimal e¡ect on
PDGF-BB- and FGF-2-induced elevations in these type I re-
ceptors; it had no e¡ect on PDGF-BB-induced elevations in
ALK-5 mRNA and only reduced the ALK-2 mRNA by 17%.
While the antibody attenuated FGF-2-induced increases in
ALK-5 mRNA by approximately 9% it had more potent ef-
fects on ALK-2 mRNA levels, which were reduced by 55%
(Fig. 4). The antibody did not a¡ect the levels of mRNA
encoding these receptor types in the absence of growth factor
stimulation (not shown). Thus, PDGF-BB and FGF-2, at
concentrations which induce near-maximal e¡ects on VSMC
proliferation [7], exert e¡ects on ALK-5 mRNA levels that are
relatively independent of any autocrine action of bioactive
TGF-L1, while the increases they induce in ALK-2 mRNA
levels are partially dependent on TGF-L1. In contrast to the
apparent lack of dependency of the elevation in ALK-5
mRNA on TGF-L1, the PDGF-BB- and FGF-2-induced ele-
vations in TLRII mRNA levels were nearly completely de-
pendent on TGF-L1 (Fig. 4). Alone, the TGF-L1-speci¢c neu-
tralising antibody did not a¡ect basal TLRII mRNA levels
(not shown); however the increases induced by 24 h exposure
to PDGF-BB and FGF-2 were reduced by 75% and 98%,
respectively (Fig. 4). Thus, elevations in mRNAs encoding
the predominant type I receptor required for TGF-L action,
ALK-5, and its type II receptor induced by PDGF-BB and
FGF-2 exhibit a di¡erential dependency on the production of
bioactive TGF-L1.
4. Discussion
The initiation of TGF-L-induced cell signalling involves the
heteromeric association of type I and type II receptor serine/
threonine kinases, followed by transphosphorylation of the
type I receptor [10]. The large array of cellular responses
initiated by this ligand-receptor complex suggest that the ini-
tiated intracellular signals are likely to vary depending on the
requirements of the cells. Our study indicates that part of the
diversity in cell signalling by TGF-L in VSMC is mediated
through alterations in tyrosine phosphorylation. The precise
sites in the signalling cascade in cells where tyrosine phos-
phorylation creates diversity of cell responses are yet to be
fully de¢ned but likely involves tyrosine phosphorylation of
the type II TGF-L receptor since type II receptors of the
TGF-L superfamily have recently been reported to also pos-
sess tyrosine kinase activity [8,9].
Diversity of TGF-L responses in cells have been attributed
to serine and threonine dependent phosphorylation changing
the properties of the types I or type II receptor. Thus, serine-
172 and threonine-176 of the type I TGF-L (ALK-5) receptor
are dispensable for extracellular matrix production by TGF-L
but critical for its ability to inhibit cell proliferation [18]. Sim-
ilarly, phosphorylation of the glycine/serine rich (GS) domain
of ALK-5 is critical for antiproliferative and transcriptional
responses to TGF-L [19]. Phosphorylation of serine-409 in the
type II receptor is also critical for TLRII kinase signalling and
the ability of TGF-L to induce growth inhibition, whilst phos-
phorylation of serine-416 inhibits type II TGF-L receptor
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Fig. 3. Agarose gel illustrating the sRT-PCR products of mRNA obtained after 24 h stimulation of VSMC with TGF-L1 in the absence (T)
and presence (G) of 200 WM genistein. M represents molecular weight markers from xX174 DNA digested with HaeIII (Promega, WI, USA).
Results are typical of 3 similar experiments.
Fig. 4. Dependency of elevations in TGF-L receptor mRNAs on endogenously produced TGF-L1 in cultured vascular smooth muscle cells dur-
ing 24 h incubation with PDGF (P) and FGF (F) in the presence of the TGF-L neutralising antibody (ANTIBODY). C represents control
(growth factor stimulated in the absence of antibody). T indicates TGF-L1 stimulated mRNA levels in the presence of the antibody. Results
are the mean of 3 similar experiments.
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function [12]. Very recent studies indicate that the type II
TGF-L receptor is also subject to autophosphorylation on
tyrosine residues at positions 259, 336 and 424; replacement
of these residues with phenylalanine greatly attenuated the
kinase activity of the receptor in vitro but the signi¢cance
of this ¢nding in intact cells was not de¢ned [9]. Our ¢ndings
in VSMC indicate that tyrosine phosphorylation may partic-
ipate in de¢ning transcriptional responses to TGF-L1, such as
elevations in TGF-L receptor types.
In the present study PDGF-BB and FGF-2 were also
shown to induce elevations in TGF-L receptor subtypes. How-
ever, only TLRII mRNA elevations exhibited dependency on
endogenously produced TGF-L1, while ALK-2 mRNA eleva-
tions exhibited partial dependency and ALK-5 no depend-
ency. These di¡erent dependencies on endogenous TGF-L1
when the VSMC are stimulated by these growth factors which
are known to elevate TGF-L secretion [7], most likely re£ect
di¡erences in the characteristics of the promotor regions of
the receptor genes. The TLRII promotor region contains both
AP-1 and SP-1 binding sites while the ALK-5 promotor has
predominantly SP-1 binding sites [20,21]. TGF-L1 exerts many
of its e¡ects via AP-1 binding sites [22], and has recently been
reported to a¡ect activity of promotors containing SP-1 bind-
ing sites [23].
Both common and apparently independent mechanisms ap-
pear to be important in regulating the expression of types I
and II TGF-L receptors in blood vessels. In injured carotid
arteries up-regulation of both receptor types has been re-
ported [6,24] but in other vessels type I receptor serine-threo-
nine kinases are preferentially expressed [25,26]. Also in osteo-
blasts [27], during kidney development [28] and in malignancy
[29] independent changes in type I and type II receptors for
TGF-L have been reported. The present results indicate the
di¡erentiation of TGF-L signalling, altering the pro¢le of
TGF-L responses in cells, may occur by mechanisms depend-
ent on tyrosine kinases and probably involving tyrosine phos-
phorylation on TLRII. Further studies will be necessary to
understand the mechanisms by which tyrosine kinases alter
cell signals involved in the expression of TGF-L receptor
types.
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